Progyny Stock News

Progyny Inc. (NASDAQ:PGNY) price closed higher on Monday, February 07, jumping 2.95% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, t

Progyny, Inc (NASDAQ: PGNY) shares have weakened more than 20% since November 05, even though the company reported strong third-quarter results. Management expects a further business acceleration Prog

Nordea Investment Management AB grew its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 98.9% during the third quarter, HoldingsChannel.com reports. The firm owned 498,734 shares of the companys stock after purchasing an additional 248,042 shares during the period. Nordea Investment Management ABs holdings in Progyny were worth $28,418,000 at the end of the most []

Avantax Advisory Services Inc. purchased a new position in shares of Progyny, Inc. (NASDAQ:PGNY) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,784 shares of the companys stock, valued at approximately $212,000. Several other institutional investors and hedge []

Progyny Inc. (NASDAQ:PGNY)s traded shares stood at 0.64 million during the last session. At the close of trading, the stocks price was $46.80, to imply a decrease of -4.57% or -$2.24 in intraday trading. The PGNY shares 52-week high remains $68.32, putting it -45.98% down since that peak but still an impressive 22.44% since price Progyny Inc. (NASDAQ: PGNY): Can A Stock Be Up 10.40% YTD, And Still Be A Loser Read More »

Progyny, Inc. (NASDAQ:PGNY) Director Norman Payson sold 8,330 shares of the stock in a transaction dated Wednesday, December 8th. The shares were sold at an average price of $50.65, for a total value of $421,914.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this []

Progyny, Inc. (NASDAQ:PGNY) has received a consensus rating of Buy from the nine research firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a []

Progyny, Inc. (NASDAQ:PGNY) Stock analysts at Jefferies Financial Group issued their FY2021 earnings estimates for Progyny in a research report issued on Wednesday, December 1st. Jefferies Financial Group analyst G. Santangelo forecasts that the company will post earnings per share of $0.52 for the year. Jefferies Financial Group has a Buy rating and a []

Investment analysts at Jefferies Financial Group initiated coverage on shares of Progyny (NASDAQ:PGNY) in a research report issued to clients and investors on Wednesday, Analyst Price Targets reports. The brokerage set a buy rating and a $60.00 price target on the stock. Jefferies Financial Groups price target would suggest a potential upside of 22.35% from []

Quipt Home Medical (NASDAQ:QIPT) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings. Valuation & Earnings This table compares Quipt Home Medical and Progynys revenue, earnings per share (EPS) []

Prudential Financial Inc. purchased a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 8,816 shares of the companys stock, valued at approximately $520,000. A number of other institutional investors and hedge funds have also bought and sold []

Progyny, Inc. (NASDAQ:PGNY) Director Norman Payson sold 8,130 shares of the firms stock in a transaction on Tuesday, November 23rd. The stock was sold at an average price of $54.26, for a total transaction of $441,133.80. The sale was disclosed in a document filed with the SEC, which is available through this link. Norman Payson []